Valink Therapeutics
PrivateLast Round
Early Funding
Oct 20, 2025
Est. Valuation
$1.79M
Total Funding Raised
$19.73M
Momentum Score
100 /100
Company Overview
Valink Therapeutics is a biotechnology company that develops next-generation, antibody-based therapeutics to treat solid tumors. The company utilizes its proprietary modular platform, LiliumX™, to rapidly design, construct, and screen complex drug candidates, particularly bispecific antibody-drug conjugates (bsADCs). Founded in 2021 and spun out of the University of Oxford, the company rebranded from LiliumX to Valink Therapeutics in November 2023 to signify its strategic shift from a platform-focused entity to a therapeutics development company. The company is backed by investors including Y Combinator, RV Invest, and Hoxton Ventures.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Valink Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Valink Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 20, 2025 | ||||
| Seed | Nov 2, 2023 | ||||
| Accelerator | Mar 24, 2021 |
Key People
Founding team and executive leadership
Valink Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Saras Capital | Early Funding |
| Magnet Ventures | Seed |
| Oxford Science Enterprises | Early Funding |
| Acequia Capital | Seed |
| Hoxton Ventures | Seed, Early Funding |
| Oxonian Ventures | Early Funding |
| SynBioVen | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 17, 2025
Partnered with Nona Biosciences for integrated drug discovery solutions.
- Oct 20, 2025
$12M raised in early funding.
Valink Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Valink Therapeutics's valuation, stock price, and market status.
